PHARMACOGENETIC EVALUATION OF ANTI-HYPERTENSIVE RESPONSE (PEAR)

这个子项目是许多研究子项目中利用 资源由NIH/NCRR资助的中心拨款提供。子项目和 调查员(PI)可能从NIH的另一个来源获得了主要资金， 并因此可以在其他清晰的条目中表示。列出的机构是 该中心不一定是调查人员的机构。 这项研究的目的是确定大量基因与高血压患者对利尿剂和β-受体阻滞剂的反应之间的关联。它将检验这样的假设：1)候选基因的多态是降压药和B-受体阻滞剂和噻嗪类利尿剂不良反应患者间差异的重要决定因素；以及2)存在大量新基因，它们是抗高血压和B-受体阻滞剂和噻嗪利尿剂不良反应患者间差异的重要决定因素。

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to determine the association of a large number of genes with responses to diuretics and beta-blockers in hypertensive patients. It will test the hypothesis that 1) polymorphisms in proposed candidate genes are important determinants of the inter-patient variance in antihypertensive and adverse response to B-blockers and thiazide diuretics; and 2) there are a substantial number of new genes that are important determinants of the interpatient variance in antihypertensive and adverse responses to B-blockers and thiazide diuretics.